Hubert B. Josien

TL;DR: In vivo studies show that inhibition of γ-secretase has the expected benefit of reducing Aβ in a murine model of Alzheimer disease but has potentially undesirable biological effects as well, most likely because of the inhibition of Notch processing.

TL;DR: The use of CCR5 antagonists of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is -C(R13)2-, -C (R13)(R13), R19)-, -c(O)-, O-, -NH-, -N(alkyl)-, (a), (b), (c), (d), (e), (f), (g, (h), (h, (i), (j), (k, (k), (l), (m), (n) or (n

TL;DR: In this article, a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds and methods of treatment, prevention, inhibition, or amelioration of one or multiple diseases associated with the central nervous system using such compounds or pharmaceutical compositions are described.

TL;DR: In this article, the gamma secretase inhibitors of the formula were described, where R 1 is a substituted aryl or substituted heteroaryl group; R 2 is an R 1 group, alkyl, X(CO)Y, or alkylene-X( CO)Y wherein X and Y are as defined as defined herein; each R 3 and each r 3A are independently H, or Alkyl.

TL;DR: In another embodiment, the invention discloses pharmaceutical compositions comprising such melanin-concentrating hormone antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes as discussed by the authors.